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Abstract
Background: Currently, a cervical esophagogastric anastomosis (CEA) is often performed after minimally invasive
esophagectomy (MIE). However, the CEA is associated with a considerable incidence of anastomotic leakage requiring
reintervention or reoperation and moderate functional results. An intrathoracic esophagogastric anastomosis (IEA) might
reduce the incidence of anastomotic leakage, improve functional results and reduce costs. The objective of the ICAN trial
is to compare anastomotic leakage and postoperative morbidity, mortality, quality of life and cost-effectiveness between
CEA and IEA after MIE.
Methods/design: The ICAN trial is an open randomized controlled multicentre superiority trial, comparing CEA (control
group) with IEA (intervention group) after MIE. All patients with esophageal cancer planning to undergo curative MIE are
considered for inclusion. A total of 200 patients will be included in the study and randomized between the groups in a 1:1
ratio. The primary outcome is anastomotic leakage requiring reintervention or reoperation, and secondary outcomes are
(amongst others) other postoperative complications, new onset of organ failure, length of stay, mortality, benign strictures
requiring dilatation, quality of life and cost-effectiveness.
Discussion: We hypothesize that an IEA after MIE is associated with a lower incidence of anastomotic leakage requiring
reintervention or reoperation than a CEA. The trial is also designed to give answers to additional research questions
regarding a possible difference in functional outcome, quality of life and cost-effectiveness.
Trial registration: Netherlands Trial Register: NTR4333. Registered on 23 December 2013.
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Background
The annual incidence of esophageal carcinoma is in-
creasing [1]. Anastomotic leakage is an important early
postoperative complication that often results in reopera-
tion, delayed (ICU) discharge, psychological distress and
associated costs. Leak rates cited in the recent literature
range from 0–30 % [2, 3], and anastomotic leakage is the
main cause of postoperative mortality. It is estimated to
be responsible for up to 40 % of deaths following esoph-
agectomy and is associated with a prolonged ICU treat-
ment and hospital stay [3, 4]. Late complications, such
as anastomotic stricture, are also responsible for signifi-
cant morbidity. Stricture rates following esophageal
anastomosis range from 5–40 % [5].
In current practice, both intrathoracic esophagogastric
anastomosis (IEA) and cervical esophagogastric anasto-
mosis (CEA) are used worldwide to restore gastrointes-
tinal continuity after esophagectomy with gastric tube
reconstruction. Four randomized controlled trials
including a total of 267 patients have been performed
that compared the results of CEA with IEA after open
esophagectomy [2]. The mean incidence of anastomotic
leakage was 26 % after CEA and 4 % after IEA. No
significant differences between the groups were found
for mortality, pulmonary complications or hospital stay.
However, all trials performed so far have serious meth-
odological flaws. All trials are single centre studies
including a limited number of 32 to 92 patients, of
whom a substantial number was either excluded from
the analysis for unclear reasons or not reported. Further-
more, allocation concealment was not always reported
and intention-to-treat analyses not performed. All stud-
ies were performed before neoadjuvant chemoradiother-
apy was introduced, and none of the studies included
patients undergoing minimally invasive esophagectomy
(MIE). Finally, data on quality of life, functional results
and cost-effectiveness have not been studied.
Therefore, the results of the previous trials are difficult
to interpret and may not be applicable to current surgi-
cal practice. Since high-quality evidence is lacking, there
are no (inter)nationally accepted evidence-based guide-
lines for the preferred location of the esophagogastric
anastomosis.
Methods/design
Study aim
The aim of the ICAN trial is to compare anastomotic leak-
age and postoperative morbidity, mortality, quality of life
and cost-effectiveness between CEA (control group) and
IEA (intervention group) after MIE.
Design and setting
The ICAN trial is designed as an open randomized, mul-
ticentre superiority trial. Patients are randomly allocated
to undergo MIE with CEA or IEA (Table 1). The study
will be conducted in Dutch hospitals with surgeons who
are competent in performing both techniques.
Primary endpoint
The primary endpoint is anastomotic leakage for which
endoscopic, radiologic or surgical reintervention is
needed. This corresponds to the Esophagectomy Com-
plications Consensus Group (ECCG) definition of anas-
tomotic leakage type II and type III [6]. Anastomotic
leakage is defined according to the ECCG [6] as a full
thickness defect of the anastomosis. This can be identi-
fied by (1) computed tomography (CT) scan with intra-
venous and oral contrast (’swallow CT scan’), (2)
endoscopy, (3) drainage of ingested materials into the
chest tube (intervention group) or ingested materials or
saliva into the cervical wound (control group) or (4)
established anastomotic leakage during reintervention,
reoperation or autopsy. Anastomotic leakage is assessed
during treatment by the treating surgeon and a member
of the ICAN study team. In addition, a third ICAN study
team member will assess anastomotic leakage using
blinded medical reports. Leakages of the gastric tube are
scored separately and will be reported separately. If the
location of a leak is uncertain (anastomosis or gastric
tube), but it has been shown that a leak is present, this
is scored as anastomotic leakage.
Secondary endpoints
Secondary endpoints are incidence of postoperative
complications (i.e. pneumonia, pneumothorax, pleural
empyema, mediastinal abscess, cardiac complications),
severity of complications according to the modified
Clavien-Dindo classification [7] and new onset organ
failure according to the Sepsis-related Organ Failure
Assessment (SOFA) score [8]. General quality of life is
scored by EuroQol 5D, whereas cancer-specific quality
of life is assessed with the European Organization for
Research and Treatment of Cancer Quality of Life Ques-
tionnaire (EORTC-QLQ C30). To assess esophageal
cancer-specific quality of life, the EORTC-QLQ OG25
module is used. From the questionnaires, the domains of
general quality of life and eating-related quality of life
are the most important outcomes, although all domains
of the questionnaires will be assessed.
Functional outcome parameters, including dysphagia,
regurgitation, weight loss, return to preoperative weight
and the incidence of benign strictures requiring dilata-
tion are also scored. Other secondary endpoints are hos-
pital mortality, mortality after 30 and 90 days, length of
stay in the ICU and in the hospital, ICU and hospital
readmission rate, the incidence of recurrent laryngeal
nerve trauma and cost-effectiveness.
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Population
All patients with resectable esophageal carcinoma are
screened for eligibility by their esophageal surgeon.
Inclusion criteria
Inclusion criteria are age ≥18 years and histologically
proven primary esophageal adenocarcinoma or squamous
cell carcinoma. Patients are only included if the tumour is
considered resectable (cT1b-4a, N0-3, M0) and the bulk
of the tumour is located in the distal or mid esophagus
(distal to the level of the carina) or at the level of the
cardia-esophageal junction (up to Siewert II [9]).
Exclusion criteria
Exclusion criteria are previous major gastric or major
thoracic surgery rendering MIE unfeasible, prognosis
determining malignancy other than esophageal cancer,
inability to undergo curative resection and/or follow-up
and inability to provide oral or written informed consent.
Time of inclusion and randomization
In the Netherlands, most patients with resectable
tumours are scheduled to undergo neoadjuvant chemo-
radiotherapy, which is completed approximately 8 weeks
before surgery. Patients will be given information about
the trial and will be randomized after neoadjuvant
chemoradiotherapy or in the weeks before surgery if
neoadjuvant chemoradiotherapy is not indicated.
Randomization
Patients will be randomized to the intervention group or
the control group with a 1:1 ratio, using a computerized
randomization tool (Castor [10]). Patients are stratified
according to hospital in order to ensure that other local
treatment factors (i.e. postoperative care) are unlikely
to interfere with study outcome. Permuted-block
randomization with varying block size is used. Alloca-
tion and block size are concealed to all investigators.
Because of the nature of this trial involving different
surgical incisions, blinding treating surgeons and trial
participants is unfeasible: A patient will feel whether
a cervical incision has been made, and the surgeon
knows which operation has been performed. However,
a study team member will assess blinded medical reports
regarding anastomotic leakage in order to obtain blinded
assessment of the primary outcome parameter.
Patients can withdraw from the study at any time. The
operating surgeon can decide not to perform a resection
during surgery if the tumour is found to be irresectable
because of ingrowth into adjacent organs, if periopera-
tive metastases to other organs are found or if resection
is unfeasible because of other perioperative events or
findings. Modification of the intervention during surgery
is justified if the operating surgeon decides he is unable
to perform the allocated anastomosis. In this case,
follow-up continues according to the trial protocol, and
an intention-to-treat analysis will be performed.
Table 1 Schedule of enrolment, interventions and assessments
Study period
Enrolment and allocation Post-allocation Close-out
Timepoint (months) Surgery Follow-up after surgery
0 1 2.5 4 7 13 25
Enrolment:
Eligibility screen X
Informed consent X
Allocation X
Interventions:
MIE with cervical anastomosis X
MIE with intrathoracic anastomosis X
Assessments:
Baseline patient characteristics X
Baseline tumour characteristics X
QOL questionnaires X X X X X X
CE questionnaires X X X X X
Postoperative outcome data X
Pathology data X
Functional recovery data X X X X X X
Oncologic follow-up data X X X X X
QOL quality of life, CE cost-effectiveness
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Operative technique
All patients will be scheduled to undergo MIE with IEA
or CEA. For both treatment arms, an identical two-field
lymphadenectomy is performed, and a gastric tube
reconstruction with the gastric tube in the posterior
mediastinum is used. An omental wrap is performed
after IEA and CEA, since there is evidence that this
reduces the incidence of clinically relevant anastomotic
leakage [11]. Other surgical factors are left to the discre-
tion of the surgeon.
Quality control of operative technique
To prevent learning curve bias, only surgeons who have
performed at least 50 minimally invasive intrathoracic
anastomoses and >50 cervical anastomoses can partici-
pate in this trial. To ensure the quality in each partici-
pating centre, a surgical procedure is recorded upon
trial participation to evaluate the quality control of the
operation. This recording was evaluated by an expert
group of 10 other dedicated minimally invasive esopha-
geal surgeons. During this meeting, this group of experts
also discussed the results of MIE with CEA and MIE
with IEA over the last 2 years per participating centre.
Hospitals and their surgeons can only participate in the
study if the experts judged both the surgical procedure
and the results of the last 2 years as satisfactory. This
expert opinion-based approach was used because there
is currently no consensus on how surgical proficiency
should be determined. Furthermore, a video will be
recorded of each included patient. To ensure operative
quality during the trial, the principal investigator (PI) or
one of the lead investigators will evaluate the video of
every fifth randomized patient. To prevent institution-
related bias, only hospitals with a high volume (>30 eso-
phagectomies per year) are invited to participate, and
randomization will be stratified per hospital.
Data collection and data management
At inclusion, a participant number will be generated,
and this number will be used for further identification in
the database. The participant number key is accessible
by the PI and coordinating investigator. Clinical data will
be collected by the study coordinator or research nurse
and will be recorded in a good clinical practice (GCP)-
compliant digital case record form (CRF) and database
(Castor [10]). All non-electronic items containing data
are kept in locked cabinets at the data coordinating cen-
tres. The data can be accessed by the research nurse,
research physician and PI. Participating centres can
request information from the database, but will only
have access to their own centre’s data. After the study
has been completed, requests to access the dataset can
be submitted to the PI. The completed CRFs will also be
checked with the source data regarding the primary
outcome parameter and important secondary outcome
parameters.
Follow-up
For each participant, the study will start at randomization
and the subject will be followed until 24 months after sur-
gery. The primary outcome parameter will be evaluated
3 months after surgery. During the remaining 21 months
of the follow-up, data on readmission, functional results,
quality of life and cost-effectiveness will be generated.
Study visits are scheduled to take place 2 weeks before
surgery, 6 weeks after surgery and after 3, 6, 12 and
24 months.
Strategies to improve adherence to recruitment and
intervention protocols
Surgeons and local research nurses will receive email
messages 1–2 days before an eligible patient visits their
outpatient clinic. Inclusion rate feedback will be
provided every 3 months in an electronic newsletter.
Completeness of CRF data and the adherence to study
protocol will be checked on a weekly basis by the coord-
inating investigator or research nurse, in addition to the
monitoring procedure. A yearly investigators meeting
will be held.
Safety and monitoring
An independent data safety monitoring committee
(DSMC) will evaluate the progress of the trial and will
examine safety variables. The DSMC consists of a
surgeon, a randomized controlled trial specialist and a
statistician. Individualized patient description charts in-
cluding safety parameters will be presented to the DSMC
including one table comprising these endpoints in blinded
groups for every 30 patients. The main safety parameters
are all serious adverse events (SAEs) and include mortal-
ity, multiple organ failure, anastomotic leakage, pulmon-
ary complication rate, cardiovascular complication rate,
reinterventions and reoperation.
After the investigators have presented the data, the
members of the DSMC will discuss these results in the
absence of the investigators and will then advise them.
Possible options will include continuing the trial,
performing an interim analysis, adjusting the trial’s
design and discontinuing the trial. Discontinuation will
be advised if the DSMC concludes that the results would
convince a broad range of clinicians that one trial
arm is inferior or if safety is compromised in one
arm. If the DSMC advises to adjust the trial’s design,
to perform an interim analysis or to discontinue the
trial, the responsible medical ethical committee will
also be notified. SAEs will be reported to the Central
Committee on Research involving Human Subjects
using an online module [12].
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The ICAN trial will be monitored according to the
Dutch federation of universities guidelines. Since both
interventions that are being investigated are considered
to be standard care in the Netherlands, this is a low-risk
study. The conduction of the trial will be monitored in
two visits per participating site, and the monitor will
check trial processes in 5 % of the included patients.
Sample size calculation
The incidence of anastomotic leakage requiring reinter-
vention or reoperation (type II or III [6]) after CEA is
estimated to be 25 % [2, 13], and this is estimated to be
10 % after IEA [2, 3]. This estimation also corresponds
to data from our own database in which data on morbid-
ity after esophageal resection is collected from three of
the participating hospitals, and this difference is consid-
ered to be clinically relevant. Based on a superiority trial
design and taking an alpha of 0.05 and a power of 80 %,
100 patients per treatment arm should be included.
Statistical analysis
Analyses will be carried out according to the intention-
to-treat principle. For dichotomous data, frequencies will
be presented, and continuous data will be presented as
mean and standard deviation or median and range. The
main outcome parameter in the two groups will be com-
pared by calculating both the risk difference and relative
risks with their 95 % confidence intervals. An additional
per-protocol analysis will be done to evaluate the effect-
iveness of the intervention with regard to the actual
treatment received. Differences in quality of life (as
scored by the validated EuroQol 5D, EORTC-QLQ C30
and EORTC-QLQ OG25 questionnaires) will be ana-
lysed using a Mann-Whitney test.
Subgroup analysis will be performed on the type and
configuration of anastomosis (i.e. side-to-end, side-to-
side or end-to-end). Further subgroup analysis will only
be carried out in case of significant interaction effects.
Potential modification of the effect of each intervention
will be evaluated with Poisson analyses.
Patients with open and closed procedures are replaced
with new subjects. In the case of missing data, we will
perform Poisson regression analyses with a robust
covariance matrix estimator to adjust for covariates,
since it has been shown that complete case analysis with
covariate adjustment and multiple imputation yield simi-
lar estimates in the event of outcome data that are miss-
ing at random [14]. In addition, we will perform a
sensitivity analysis in which a complete case analysis is
compared to the multiple imputation analysis, in order
to investigate whether multiple imputation would lead
to different results.
Discussion
The use of MIE is increasing worldwide, because it has
been shown to reduce postoperative morbidity [15, 16]. A
recent worldwide questionnaire study with 478 responders
showed that approximately 55 % of surgeons prefer IEA
after MIE and that there is a strong trend towards an in-
creased use of IEA instead of CEA for reconstruction of
the gastrointestinal tract [17]. However, there is currently
no high-quality evidence available that favours IEA over
CEA after MIE in terms of anastomotic leakage, other
postoperative morbidity, functional results, quality of life
or costs. In addition, IEA after MIE is a technically de-
manding procedure and can be accompanied by consider-
able postoperative morbidity, probably because of a long
learning curve [18, 19]. Without evidence for a benefit of
IEA over CEA and in the presence of learning curve asso-
ciated morbidity, the use of an intrathoracic anastomosis
as the standard reconstruction after MIE is questioned.
In theory, both anastomotic locations have possible
benefits. Historically, the cervical anastomosis was
introduced in order to minimize the disastrous effects of
intrathoracic anastomotic leakage [20]. Cervical anasto-
motic leakage can sometimes be managed by bedside
opening [21], although severe intrathoracic complications
of cervical leaks have been described [22]. Intrathoracic
anastomotic leak used to be associated with a high postop-
erative mortality of 60 % [21]. However, in the modern
era, endoscopic, radiologic and surgical possibilities for
treatment of intrathoracic anastomotic leakage have
become available, and it now seems a manageable
complication [23]. Benefits of the IEA are a lower in-
cidence of anastomotic leakage [2] and possibly a
lower incidence of benign strictures requiring dilata-
tion [24–26]. A better healing of the IEA might be
explained by resecting the relatively ischemic tip of
the gastric tube, providing better vascularized tissue
for anastomosis [21, 27]. If IEA proves to be a safe
surgical technique, it might be preferred over CEA.
This study is designed to answer the question of
whether an IEA or CEA is preferred after MIE. For this
trial to succeed, it is essential that all participating cen-
tres are surgical experts in the creation of both IEA and
CEA in order to avoid the influence of a learning curve,
which is the rationale for strict centre invitation and
quality control procedures. The ICAN trial will provide
important data on anastomotic leakage, other postopera-
tive morbidity, mortality, quality of life, functional
results and cost-effectiveness up to 2 years after MIE.
The results will aid in clinical decision for the location
of the anastomosis and can provide useful information
that can be incorporated into future guidelines.
Trial status
The trial has been recruiting since May 2016.
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